Get detailed information on Ranitidine, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated prescription ...

GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S. lawsuits that alleged its discontinued heartburn drug Zantac caused cancer.

Operating profit at GSK fell by 86 per cent due to a charge related to the settlement of Zantac settlements the company said ...

The British drugmaker’s settlement with 10 separate law firms resolves 93% of all U.S. cases currently filed against GSK over claims its popular Zantac drug contained the carcinogen N ...

GSK launched Zantac in 1981 and it was first approved for sale in the US in 1983 as a prescription medication. It went on to become the world's best-selling drug, with annual sales in excess of $1bn.

GSK Plc said it will pay as much as $2.2 billion to resolve about 80,000 US court cases related to allegations that its old reflux medication Zantac was contaminated with a suspected carcinogen.

GSK shares jumped on Thursday after the UK drugmaker reached a settlement of up to $2.2bn to resolve the vast majority of cases linked to its heartburn medicine Zantac.

Zantac, first sold in the US in 1983, was one of the best-selling medicines globally, bringing in more than $1bn (€0.91bn) in sales per year. It was also sold by Sanofi, a French drug company ...

has announced that it has agreed to settle nearly 80,000 state-level Zantac cases. The lawsuits claimed that the now-discontinued version of the heartburn drug caused cancer, although GSK says ...

GSK is on track to achieve its guidance for 2024, with its Q3 2024 and 9m 2024 results today. Explore more details here.

British pharmaceutical company GSK on Wednesday said it swung into a net loss in the third quarter after settling lawsuits in the United States surrounding its Zantac heartburn drug. GSK suffered ...